Clovis Oncology Inc - ESG Rating & Company Profile powered by AI
If you are employed by Clovis Oncology Inc and you wish to use your Sustainability aseessment, please get in touch. The page contains a questions and answers section for Clovis Oncology Inc. Alternative corporations in the rating industry group for Clovis Oncology Inc are displayed below.
Clovis Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.1; made up of an environmental score of 4.8, social score of 6.4 and governance score of 6.7.
6.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 586 | Traphaco JSC | 6.2 | High |
| 586 | Xenon Pharmaceuticals Inc | 6.2 | High |
| 623 | Clovis Oncology Inc | 6.1 | High |
| 623 | Achieve Life Sciences Inc | 6.1 | High |
| 623 | Anatara Lifesciences Ltd | 6.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Clovis Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Clovis Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Clovis Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes Clovis Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Clovis Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Clovis Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Clovis Oncology Inc offer flexible work?
Sign up for free to unlockDoes Clovis Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Clovis Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Clovis Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes Clovis Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Clovis Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Clovis Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Clovis Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Clovis Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Clovis Oncology Inc disclose water use targets?
Sign up for free to unlockDoes Clovis Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Clovis Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes Clovis Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Clovis Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Clovis Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Clovis Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes Clovis Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Clovis Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Clovis Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Clovis Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Clovis Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Clovis Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Clovis Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Clovis Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Clovis Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes Clovis Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes Clovis Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Clovis Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes Clovis Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Clovis Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Clovis Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.